Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and/or myocarditis

Kenji Kufukihara, Yurika Watanabe, Takashi Inagaki, Koutaro Takamatsu, Shunya Nakane, Jin Nakahara, Yukio Ando, Shigeaki Suzuki

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The purposes of the present study were to identify anti-striational antibodies in myasthenia gravis (MG) patients with myositis and/or myocarditis using a combination of cell-based assays and flow cytometry (cytometric cell-based assays) and to describe the main clinical implications. Among 2,609 stored samples collected from all over Japan between 2003 and 2016, we had serum samples from 30 MG patients with myositis and/or myocarditis. Cytometric cell-based assays with titin, ryanodine receptor, and voltage-gated Kv1.4 were performed. Autoantibodies were determined by differences in phycoerythin fluorescence between the 293F cells and titin-transfected cells. MG patients with myositis and/or myocarditis as well as late-onset and thymoma-associated MG had anti-titin, anti-ryanodine receptor, and anti-Kv1.4 antibodies. In contrast, patients with early-onset MG, those with other myopathies and healthy controls did not have anti-titin or anti-Kv1.4 antibodies with some exceptions, but they possessed anti-ryanodine receptor antibodies. Thirty MG patients with myositis and/or myocarditis showed a severe generalized form, and 21 of them had thymoma. Anti-titin and anti-Kv1.4 antibodies were found in 28 (93%) and 15 (50%) patients, respectively, and all patients had at least one of these antibodies. Cytometric cell-based assays thus demonstrated that anti-striational antibodies are biomarkers of MG with myositis and/or myocarditis.

Original languageEnglish
Article number5284
JournalScientific reports
Volume9
Issue number1
DOIs
Publication statusPublished - 2019 Dec 1

Fingerprint

Myositis
Myasthenia Gravis
Myocarditis
Connectin
Anti-Idiotypic Antibodies
Ryanodine Receptor Calcium Release Channel
Thymoma
Antibodies
Muscular Diseases
Autoantibodies
Flow Cytometry
Japan
Biomarkers
Fluorescence
Serum

ASJC Scopus subject areas

  • General

Cite this

Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and/or myocarditis. / Kufukihara, Kenji; Watanabe, Yurika; Inagaki, Takashi; Takamatsu, Koutaro; Nakane, Shunya; Nakahara, Jin; Ando, Yukio; Suzuki, Shigeaki.

In: Scientific reports, Vol. 9, No. 1, 5284, 01.12.2019.

Research output: Contribution to journalArticle

Kufukihara, Kenji ; Watanabe, Yurika ; Inagaki, Takashi ; Takamatsu, Koutaro ; Nakane, Shunya ; Nakahara, Jin ; Ando, Yukio ; Suzuki, Shigeaki. / Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and/or myocarditis. In: Scientific reports. 2019 ; Vol. 9, No. 1.
@article{0d7238cbb04d45bb8df2911cbd3a2ac3,
title = "Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and/or myocarditis",
abstract = "The purposes of the present study were to identify anti-striational antibodies in myasthenia gravis (MG) patients with myositis and/or myocarditis using a combination of cell-based assays and flow cytometry (cytometric cell-based assays) and to describe the main clinical implications. Among 2,609 stored samples collected from all over Japan between 2003 and 2016, we had serum samples from 30 MG patients with myositis and/or myocarditis. Cytometric cell-based assays with titin, ryanodine receptor, and voltage-gated Kv1.4 were performed. Autoantibodies were determined by differences in phycoerythin fluorescence between the 293F cells and titin-transfected cells. MG patients with myositis and/or myocarditis as well as late-onset and thymoma-associated MG had anti-titin, anti-ryanodine receptor, and anti-Kv1.4 antibodies. In contrast, patients with early-onset MG, those with other myopathies and healthy controls did not have anti-titin or anti-Kv1.4 antibodies with some exceptions, but they possessed anti-ryanodine receptor antibodies. Thirty MG patients with myositis and/or myocarditis showed a severe generalized form, and 21 of them had thymoma. Anti-titin and anti-Kv1.4 antibodies were found in 28 (93{\%}) and 15 (50{\%}) patients, respectively, and all patients had at least one of these antibodies. Cytometric cell-based assays thus demonstrated that anti-striational antibodies are biomarkers of MG with myositis and/or myocarditis.",
author = "Kenji Kufukihara and Yurika Watanabe and Takashi Inagaki and Koutaro Takamatsu and Shunya Nakane and Jin Nakahara and Yukio Ando and Shigeaki Suzuki",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-41730-z",
language = "English",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and/or myocarditis

AU - Kufukihara, Kenji

AU - Watanabe, Yurika

AU - Inagaki, Takashi

AU - Takamatsu, Koutaro

AU - Nakane, Shunya

AU - Nakahara, Jin

AU - Ando, Yukio

AU - Suzuki, Shigeaki

PY - 2019/12/1

Y1 - 2019/12/1

N2 - The purposes of the present study were to identify anti-striational antibodies in myasthenia gravis (MG) patients with myositis and/or myocarditis using a combination of cell-based assays and flow cytometry (cytometric cell-based assays) and to describe the main clinical implications. Among 2,609 stored samples collected from all over Japan between 2003 and 2016, we had serum samples from 30 MG patients with myositis and/or myocarditis. Cytometric cell-based assays with titin, ryanodine receptor, and voltage-gated Kv1.4 were performed. Autoantibodies were determined by differences in phycoerythin fluorescence between the 293F cells and titin-transfected cells. MG patients with myositis and/or myocarditis as well as late-onset and thymoma-associated MG had anti-titin, anti-ryanodine receptor, and anti-Kv1.4 antibodies. In contrast, patients with early-onset MG, those with other myopathies and healthy controls did not have anti-titin or anti-Kv1.4 antibodies with some exceptions, but they possessed anti-ryanodine receptor antibodies. Thirty MG patients with myositis and/or myocarditis showed a severe generalized form, and 21 of them had thymoma. Anti-titin and anti-Kv1.4 antibodies were found in 28 (93%) and 15 (50%) patients, respectively, and all patients had at least one of these antibodies. Cytometric cell-based assays thus demonstrated that anti-striational antibodies are biomarkers of MG with myositis and/or myocarditis.

AB - The purposes of the present study were to identify anti-striational antibodies in myasthenia gravis (MG) patients with myositis and/or myocarditis using a combination of cell-based assays and flow cytometry (cytometric cell-based assays) and to describe the main clinical implications. Among 2,609 stored samples collected from all over Japan between 2003 and 2016, we had serum samples from 30 MG patients with myositis and/or myocarditis. Cytometric cell-based assays with titin, ryanodine receptor, and voltage-gated Kv1.4 were performed. Autoantibodies were determined by differences in phycoerythin fluorescence between the 293F cells and titin-transfected cells. MG patients with myositis and/or myocarditis as well as late-onset and thymoma-associated MG had anti-titin, anti-ryanodine receptor, and anti-Kv1.4 antibodies. In contrast, patients with early-onset MG, those with other myopathies and healthy controls did not have anti-titin or anti-Kv1.4 antibodies with some exceptions, but they possessed anti-ryanodine receptor antibodies. Thirty MG patients with myositis and/or myocarditis showed a severe generalized form, and 21 of them had thymoma. Anti-titin and anti-Kv1.4 antibodies were found in 28 (93%) and 15 (50%) patients, respectively, and all patients had at least one of these antibodies. Cytometric cell-based assays thus demonstrated that anti-striational antibodies are biomarkers of MG with myositis and/or myocarditis.

UR - http://www.scopus.com/inward/record.url?scp=85063602926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063602926&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-41730-z

DO - 10.1038/s41598-019-41730-z

M3 - Article

C2 - 30918333

AN - SCOPUS:85063602926

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 5284

ER -